Navigation Links
SMT Research & Development, Ltd. Names Shuki Porath as Vice President and General Manager, Announces TCT Presence
Date:11/8/2011

SAN FRANCISCO and HERZLIYA PITUACH, Israel, Nov. 8, 2011 /PRNewswire/ -- The 23rd Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference -- SMT Research & Development, Ltd. ("SMT") today announced that Shuki Porath has joined the company as Vice President and General Manager.  Mr. Porath will be responsible for overseeing the day-to-day operations in the company's development and production facility in Herzliya Pituach, Israel, and will also play a key role in developing and implementing the company's product, clinical, regulatory and commercialization strategies.  SMT is developing a proprietary embolic deflection device designed for use during Transcatheter Aortic Valve Implantation ("TAVI") and other complex structural heart procedures.  The company's mission is to help reduce the incidence of brain injury (stroke and so-called "silent stroke") during TAVI procedures.  Mr. Porath will report to SMT's Chief Executive Officer, Paul Zalesky, Ph.D.

(Photo:  http://photos.prnewswire.com/prnh/20111108/LA01049)

"I am pleased to welcome Shuki to the SMT team," Dr. Zalesky said. "TAVI is one of the most promising and exciting medical device innovations in years.  The recent approval for marketing by the FDA of the first TAVI device highlights the potential.  Having said that, for this technology to reach its full potential and eventually extend its surgery-avoidance benefits to younger, less sick patients, it is clear that the risk of stroke and so-called "silent stroke" associated with these devices must be addressed.  Our company is  focused on that goal with the development of our embolic deflection device.  The addition Mr. Porath, a seasoned device executive, will significantly accelerate the development and commercialization process."

Prior to joining SMT in November 2011, Mr. Porath served as CEO at SeamVad Ltd, a medical device start-up company developing disposables for vascular surgery, and was CEO at ES Vascular Ltd., developer and manufacturer of innovative open and endovascular aortic staplers for AAA procedures. Formerly, Mr. Porath served as a Senior Executive at Biosense Webster, a Johnson & Johnson Company. During his 10 year tenure with Biosense Webster -- the market leader in guided applications and products for Electrophysiology -- Mr. Porath held various executive positions in the areas of product management, business development, and clinical applications.  Mr. Porath holds a BS in Electrical Engineering, an MS in Industrial Engineering and MBA -- all received from the Technion, Israel Institute of Technology, Haifa, Israel.

TCT Presence

Learn more about SMT's development activities and clinical research at booth #511 at the Cardiovascular Research Foundation's (CRF) 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) Conference, scheduled for November 7 - 11, 2011 in San Francisco.  We also invite you to visit our new web site at www.smtmed.com

About SMT

SMT is developing cerebral protection devices designed to reduce the incidence of brain injury (stroke and so-called "silent stroke") during complex catheter-based interventions.  Our initial product is designed for use during TAVI procedures and is specifically configured to protect all three aortic arch take-offs leading to the brain. Our existing device has undergone extensive testing, including FIM studies in Europe.  Clinical studies are planned in Europe and Canada, with CE Marking expected in 2012. We are actively collaborating with renowned cardiologists in the US, Europe, and Canada. SMT's executive team has extensive experience in the interventional cardiology field and venture capital backing is provided by OrbiMed Advisors, LLC, one of the largest dedicated healthcare fund managers in the world.  SMT's device is currently for investigational use only.


'/>"/>
SOURCE SMT Research & Development, Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Critical Alerts For Barrick Gold, Molycorp, Lockheed Martin, Teva Pharmaceutical, and Tenaris Released By Seven Summits Research
2. Kensey Nash Corporation Receives $1.9m NIH Grant for Tendon Product Research
3. Caliper Launches New Platform for Drug Safety Prediction and Oncology Research
4. JDRF and the Helmsley Charitable Trust Form a Collaboration to Accelerate Innovative Type 1 Diabetes Research and Development
5. Anaheim to Host Worlds Largest Gathering on Cystic Fibrosis Research and Care
6. Renal Research Institute Announces Scientific Presentations at the American Society of Nephrology Kidney Week
7. Rock Creek Pharmaceuticals Announces Completion of Medical Conferences on Anatabloc™ Research, Comments on Research Presentation at American Thyroid Association Annual Meeting
8. CVS Caremark Sponsored Research Finds Twenty Four Percent of New Prescriptions Never Filled
9. Leading Pharmaceutical Companies & Research Institutions Offer IP and Expertise for Use in Treating Neglected Tropical Diseases as Part of WIPO Re:Search
10. Sectra Signs Medical Imaging Research Agreement With University Hospitals in Cleveland
11. China Botanic Hosts Technical Exchange for Industry Research Experts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... ... 2016 , ... People across the U.S. are sharpening their pencils and honing ... contest in which patients and their families pay tribute to a genetic counselor by ... Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
Breaking Medicine News(10 mins):